Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Radiance Begins Trial for ROR-1 Targeted ADC in Blood and Solid Cancers
Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : RB-164
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Radiance Clears FDA IND for RB-164 ADC in Hematologic Cancers
Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : RB-164
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RB-164
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Megalith Pharmaceuticals
Deal Size : $1,165.0 million
Deal Type : Licensing Agreement
Radiance Biopharma Enters Exclusive License for ROR-1 Targeted Antibody Drug Conjugate
Details : Under the licensing agreement, Radiance will be responsible for the development and commercialization of SYS6005 (RB-164), a novel clinical stage ADC targeting ROR-1 for treating neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $15.0 million
February 19, 2025
Lead Product(s) : RB-164
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Megalith Pharmaceuticals
Deal Size : $1,165.0 million
Deal Type : Licensing Agreement
Lead Product(s) : YH012
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocytogen Enters Agreement for Bispecific Antibody Drug Conjugate with Radiance Biopharma
Details : Radiance has an option to license YH012, a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate from Biocytogen, for worldwide therapeutic development.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : YH012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement